Skip to content
Inciteful Med

Understanding the Types of Osteogenesis Imperfecta

Last updated:

Osteogenesis Imperfecta (OI) is classified into different types based on clinical severity and genetics, ranging from mild (Type I) to severe (Type II and III). Knowing your child's specific type helps doctors predict fracture risks, monitor for complications, and tailor a treatment plan.

Key Takeaways

  • • The Sillence classification system divides most cases of Osteogenesis Imperfecta into four primary types based on severity and clinical features.
  • • Type I is the mildest and most common form, resulting from a quantitative defect where the body produces insufficient amounts of normal collagen.
  • • Type III is a severe form caused by a qualitative defect, where malformed collagen leads to frequent fractures and progressive bone bowing.
  • • Type V is a unique genetic variation characterized by unusually large bone calluses during fracture healing and restricted forearm rotation.
  • • Identifying a child's specific OI type allows medical teams to customize treatments, such as intramedullary rodding, physical therapy, or bone-strengthening medications.

When you first receive a diagnosis of Osteogenesis Imperfecta (OI), one of the first things your doctor will discuss is your child’s Type. In the world of OI, “Type” is more than just a label; it is a clinical roadmap that helps doctors predict the severity of the condition, understand the underlying genetics, and tailor a treatment plan for your child [1][2].

The Foundation: The Sillence Classification

In 1979, a doctor named David Sillence created the foundational system for categorizing OI based on clinical and radiographic (X-ray) features [3][4]. This system, still used today, divides most cases into four primary types:

  • Type I (Mild): This is the most common form [4]. Children with Type I typically have a quantitative defect—meaning their body makes high-quality collagen, just not enough of it [5]. They usually have near-normal stature, minimal bone deformity, and fractures that may decrease after puberty [3][6].
  • Type II (Perinatal Lethal): This is the most severe form, characterized by extreme bone fragility and severe bowing [6]. Because of the severe impact on the skeleton and lungs, most babies with Type II do not survive long after birth [4][6].
  • Type III (Severe, Progressively Deforming): This type involves a qualitative defect where the collagen itself is malformed [7]. It is characterized by frequent fractures (often starting at birth), short stature, and progressive bowing of the long bones and spine [3][4].
  • Type IV (Moderate): This type sits between Type I and Type III in terms of severity [4]. Children with Type IV may have moderate bone deformity and short stature, and their sclera (the whites of the eyes) may be white or gray rather than the blue often seen in Type I [3].

The Expanded View: Types V and Beyond

As our understanding of genetics has grown, the classification system has expanded significantly. Researchers have identified over 20 different types of OI caused by mutations in genes other than the classic COL1A1 and COL1A2 [7][8].

The Unique Case of Type V

Type V is distinct from all other forms of OI because it is caused by a specific mutation in the IFITM5 gene [9][10]. It has very specific clinical features that your doctor will look for:

  • Hyperplastic Callus: When a bone breaks, the body forms a “callus” to heal it. In Type V, this callus can grow unusually large and exuberant [9][11].
  • Interosseous Membrane Calcification: The flexible membrane between the two bones in the forearm (radius and ulna) can turn into bone, which may limit a child’s ability to rotate their wrist [12][13].
  • No Blue Sclera or DI: Unlike many other types, children with Type V usually do not have blue sclera or brittle teeth (dentinogenesis imperfecta) [12][11].

Recessive Types (VI–XX+)

While the classic Sillence types are usually autosomal dominant (one copy of the gene from one parent is enough), many of the newer types are autosomal recessive (requiring a mutated gene from both parents) [7][14]. These types are often grouped by how they affect the body:

  • Collagen Folding and Processing: Genes like CRTAP or P3H1 help the collagen “fold” correctly [15][16].
  • Mineralization: Genes like TMEM38B affect how the bone matrix hardens [17][18].
  • Osteoblast Function: Some mutations affect the cells (osteoblasts) that build new bone [18][19].

Why “Type” Matters for You

Knowing your child’s Type is not just about a name; it provides a framework for the future. For example, knowing a child has Type III tells the medical team to prioritize early intramedullary rodding (placing supports inside the bones) to prevent bowing [20][21]. Conversely, a Type I diagnosis might lead to a more conservative approach focused on physical therapy and safe handling [20][22].

By integrating the clinical Sillence Type with specific genetic findings, your care team can create a “genomic co-descriptor” that offers the most accurate picture of your child’s health and treatment needs [1][2].

Frequently Asked Questions

What is the difference between mild and severe Osteogenesis Imperfecta?
Mild OI (Type I) typically involves making normal collagen but not enough of it, leading to fewer deformities. Severe OI (Type III) involves improperly formed collagen, resulting in frequent fractures, short stature, and progressive bone bowing.
What does a quantitative vs. qualitative collagen defect mean in OI?
A quantitative defect means the body makes good quality collagen but in insufficient amounts, usually seen in milder OI. A qualitative defect means the collagen structure itself is abnormal, which typically causes more severe bone fragility and deformity.
What makes Type V Osteogenesis Imperfecta unique?
Type V is caused by a specific gene mutation and has unique features like abnormally large bone growths (hyperplastic callus) when healing from fractures. It can also cause calcification between forearm bones, limiting wrist movement, and usually does not feature blue eyes or brittle teeth.
How does knowing my child's OI type affect their treatment?
Knowing the specific type helps doctors anticipate complications and tailor treatments. For example, severe types may require early surgical support with rods inside the bones to prevent bowing, while milder types might focus more on physical therapy and safe handling.

Questions for Your Doctor

  • • Based on my child's X-rays and physical exam, which Sillence Type (I, III, or IV) best describes their current clinical presentation?
  • • Does my child have a qualitative collagen defect, and if so, how does that change the expected frequency of fractures compared to a quantitative defect?
  • • Is there any evidence of Type V OI, such as 'hyperplastic callus' (large bone growths) during fracture healing or calcification of the membranes between the arm bones?
  • • Do we need to see any other specialists, like a pulmonologist or a cardiologist, specifically because of the risks associated with my child's OI Type?
  • • How does my child's specific Type influence the decision-making process for starting bone-strengthening medications like bisphosphonates?

Questions for You

  • • How has the doctor's description of our child's 'Type' changed our expectations for their mobility and daily activities?
  • • Are we comfortable explaining the difference between 'mild' (Type I) and 'severe' (Type III) to family members who might not understand the range of the condition?
  • • What are our primary goals for our child's mobility, and how can we work with the medical team to reach them based on our child's specific Type?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A Dyadic Nosology for Osteogenesis Imperfecta and Bone Fragility Syndromes 2024.

    Sillence DO

    Calcified tissue international 2024; (115(6)):873-890 doi:10.1007/s00223-024-01248-7.

    PMID: 38942908
  2. 2

    From Genetics to Clinical Implications: A Study of 675 Dutch Osteogenesis Imperfecta Patients.

    Storoni S, Verdonk SJE, Zhytnik L, et al.

    Biomolecules 2023; (13(2)) doi:10.3390/biom13020281.

    PMID: 36830650
  3. 3

    Evidence for a Role for Nanoporosity and Pyridinoline Content in Human Mild Osteogenesis Imperfecta.

    Paschalis EP, Gamsjaeger S, Fratzl-Zelman N, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2016; (31(5)):1050-9 doi:10.1002/jbmr.2780.

    PMID: 26748579
  4. 4

    Current Overview of Osteogenesis Imperfecta.

    Deguchi M, Tsuji S, Katsura D, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(5)) doi:10.3390/medicina57050464.

    PMID: 34068551
  5. 5

    Genotype-based comparison of bone microstructure in adult patients with classical osteogenesis imperfecta.

    Bartosik M, Prengel M, Delsmann J, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2026; (37(1)):231-241 doi:10.1007/s00198-025-07774-w.

    PMID: 41364339
  6. 6

    Osteogenesis Imperfecta Type II: The Lethal Newborn Form Diagnosed in the Postnatal Period.

    Elhaddadi H, Ayyad A, Messaoudi S, Amrani R

    Cureus 2024; (16(5)):e60945 doi:10.7759/cureus.60945.

    PMID: 38910652
  7. 7

    Molecular drivers of osteogenesis imperfecta: a cellular and extracellular collagen disease.

    Cotti S, Pérez Franco W, Forlino A

    Clinical science (London, England : 1979) 2025; (139(24)) doi:10.1042/CS20255642.

    PMID: 41410595
  8. 8

    Classification of osteogenesis imperfecta.

    Fratzl-Zelman N, Misof BM, Roschger P, Klaushofer K

    Wiener medizinische Wochenschrift (1946) 2015; (165(13-14)):264-70 doi:10.1007/s10354-015-0368-3.

    PMID: 26208476
  9. 9

    Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.

    Jovanovic M, Guterman-Ram G, Marini JC

    Endocrine reviews 2022; (43(1)):61-90 doi:10.1210/endrev/bnab017.

    PMID: 34007986
  10. 10

    [Genetic mutation and clinical features of osteogenesis imperfecta type V].

    Guan S, Bai X, Wang Y, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2017; (34(6)):797-801 doi:10.3760/cma.j.issn.1003-9406.2017.06.003.

    PMID: 29188603
  11. 11

    Retrospective analyses of clinical features in 28 Chinese patients with type V osteogenesis imperfecta: new perspectives in an old issue.

    Tan Z, Shek HT, Dong Z, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2023; (34(2)):369-377 doi:10.1007/s00198-022-06581-x.

    PMID: 36456709
  12. 12

    Clinical and Molecular Characterization of Osteogenesis Imperfecta Type V.

    Brizola E, Mattos EP, Ferrari J, et al.

    Molecular syndromology 2015; (6(4)):164-72 doi:10.1159/000439506.

    PMID: 26648832
  13. 13

    Interferon-Induced Transmembrane Protein 5 Mutation Causing Type-V Osteogenesis Imperfecta: A Case Report.

    Mathew SE, Santhanam M, Madhuri V

    JBJS case connector 2015; (5(1)):e15 doi:10.2106/JBJS.CC.N.00122.

    PMID: 29252448
  14. 14

    [Genotypes and phenotypes of nine Uygur children with osteogenesis imperfecta in Xinjiang].

    Luo YF, Dilihuma J, Sun GH, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(2)):135-139 doi:10.3760/cma.j.issn.0578-1310.2020.02.013.

    PMID: 32102151
  15. 15

    Crtap and p3h1 knock out zebrafish support defective collagen chaperoning as the cause of their osteogenesis imperfecta phenotype.

    Tonelli F, Cotti S, Leoni L, et al.

    Matrix biology : journal of the International Society for Matrix Biology 2020; (90()):40-60 doi:10.1016/j.matbio.2020.03.004.

    PMID: 32173581
  16. 16

    Developmental Stage-dependent Regulation of Prolyl 3-Hydroxylation in Tendon Type I Collagen.

    Taga Y, Kusubata M, Ogawa-Goto K, Hattori S

    The Journal of biological chemistry 2016; (291(2)):837-47 doi:10.1074/jbc.M115.686105.

    PMID: 26567337
  17. 17

    Atypical cell death and insufficient matrix organization in long-bone growth plates from Tric-b-knockout mice.

    Ichimura A, Miyazaki Y, Nagatomo H, et al.

    Cell death & disease 2023; (14(12)):848 doi:10.1038/s41419-023-06285-y.

    PMID: 38123563
  18. 18

    A homozygous pathogenic missense variant broadens the phenotypic and mutational spectrum of CREB3L1-related osteogenesis imperfecta.

    Guillemyn B, Kayserili H, Demuynck L, et al.

    Human molecular genetics 2019; (28(11)):1801-1809 doi:10.1093/hmg/ddz017.

    PMID: 30657919
  19. 19

    Homozygous Loss-of-Function Mutations in CCDC134 Are Responsible for a Severe Form of Osteogenesis Imperfecta.

    Dubail J, Brunelle P, Baujat G, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2020; (35(8)):1470-1480 doi:10.1002/jbmr.4011.

    PMID: 32181939
  20. 20

    Telescopic rodding in children: Technical progression from Dubow-Bailey to Fassier-Duval™.

    Fassier A

    Orthopaedics & traumatology, surgery & research : OTSR 2021; (107(1S)):102759 doi:10.1016/j.otsr.2020.102759.

    PMID: 33316440
  21. 21

    A Fracture From a Physical Exam: A Case Report of Osteogenesis Imperfecta and the Use of Fassier-Duval Rods.

    Rella RT, Brandon AS, Garrison IA, et al.

    Cureus 2023; (15(4)):e37068 doi:10.7759/cureus.37068.

    PMID: 37153255
  22. 22

    Functional Outcome of Humeral Rodding in Children With Osteogenesis Imperfecta.

    Ashby E, Montpetit K, Hamdy RC, Fassier F

    Journal of pediatric orthopedics 2018; (38(1)):49-53 doi:10.1097/BPO.0000000000000729.

    PMID: 26866647

This page explains Osteogenesis Imperfecta classifications for educational purposes. Always consult your child's geneticist or pediatrician to understand their specific OI type and tailored care plan.

Stay up to date

Get notified when new research about Osteogenesis imperfecta is published.

No spam. Unsubscribe anytime.